Key result
Desmopressin was used to manage excessive bleeding in a patient with osteogenesis imperfecta undergoing a major surgical procedure.
Why the study?
Does desmopressin improve excessive bleeding in a patient with Osteogenesis Imperfecta undergoing major surgery?
Case Report (n=1)
Does desmopressin improve excessive bleeding in a patient with Osteogenesis Imperfecta undergoing major surgery?
Desmopressin may be a viable option to manage excessive bleeding in patients with Osteogenesis Imperfecta during major surgery.
Desmopressin may aid bleeding control in OI surgery; hypothesis-generating and requires prospective validation before practice change.
OSTEOGENESIS imperfecta (OI), also known as brittle-bone disease, is a genetic disorder of connective tissue that causes susceptibility to fractures. In OI, these individuals have an increased risk of bleeding when undergoing surgery. The coagulation defect is related to the effect of abnormal collagen on platelet-endothelial cell interactions and capillary strength. By its action on capillary endothelial cells, desmopression, a synthetic analog of antidiuretic homone, may improve the coagulation abnormality seen in patients with OI. We describe the use of desmopressin in a patient with OI who experienced excessive bleeding in the setting of a major surgical procedure.
No takes yet. Share an insight, caveat, or question.
Keegan et al. (2002) conducted a case report in Osteogenesis Imperfecta (n=1). Desmopressin was evaluated on Bleeding. Desmopressin was used to manage excessive bleeding in a patient with osteogenesis imperfecta undergoing a major surgical procedure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: